Engelsk titel: Biological therapy in juvenile idiopathic arthritis
Läs online
Författare:
Herlin T
Email: trh@sks.aaa.dk
Språk: Dan
Antal referenser: 10
Dokumenttyp:
Artikel
UI-nummer: 08061233
Sammanfattning
In recent years the treatment of juvenile idiopathic arthritis (JIA) has undergone marked changes. There is substantial evidence that inhibitors of tumor necrosis factor alpha (TNFa) like etanercept, infliximab and adalimumab show significant efficacy when standard therapy fails, and long-term tolerability is fairly good. Patients with systemic JIA do not respond well to treatment with TNF inhibitors, but they may benefit from treatment with IL-1 and IL-6 receptor antagonists. Our knowledge is still limited regarding which patients respond to a specific biological therapy.